Prof Jennifer Woyach speaks to ecancer about updates of R/R CLL with prior exposure to Bruton’s tyrosine kinase (BTK) inhibitor and/or bcl-2 inhibitor in the Phase 1 trial of LP-168 (Rocbrutinib), a novel COVALENT and non-COVALENT BTK inhibitor.

Te results show that in patients with highly refractory CLL previously treated with BTK inhibitors and/or venetoclax, rocbrutinib demonstrated encouraging efficacy, with overall response rates up to 78–80% in key dose levels and sustained responses beyond two years of follow-up.

Notably, even patients double or triple exposed to covalent BTKi, non-covalent BTKi, and Bcl-2 inhibitors showed meaningful clinical benefit.

Prof Woyach says that these results highlight rocbrutinib’s potential as a promising option for patients with resistant CLL who currently face limited therapeutic choices.